Cts CORP
Market Movers (8-K)
NYSE
CTS
Cts CORPCTS Corporation's July 2026 investor presentation outlines a strategy focused on diversified end markets, technological innovation, and strategic M&A to achieve a 10% CAGR.
NYSE
CTS
Cts CORPCTS Corporation announced robust second quarter 2026 financial results, driven by strong diversification momentum, leading to record margins and an increased full-year outlook.
Better than expected
NYSE
CTS
Cts CORPCTS Corporation appoints Pratik Trivedi as President and CEO, effective July 6, 2026, as Kieran O'Sullivan transitions to Executive Chairman.
NYSE
CTS
Cts CORPCTS Corporation announced the results of its Annual Meeting of Shareholders held on May 14, 2026, with all director nominees elected and key proposals approved.
NYSE
CTS
Cts CORPCTS Corporation's April 2026 investor presentation outlines a strategy focused on diversified end-market growth, technological innovation, and strategic acquisitions, targeting a 10% CAGR.
NYSE
CTS
Cts CORPCTS Corporation announced robust first-quarter 2026 financial results, driven by significant growth in diversified end markets, and has narrowed its full-year guidance.
Quarterly Earnings (10-Q)
NYSE
CTS
Cts CORPCTS Corporation announced its second quarter 2026 financial results, showcasing a 7.0% increase in net sales and a significant improvement in gross margin percentage.
NYSE
CTS
Cts CORPCTS Corporation announced a significant increase in net sales and earnings for the first quarter of 2026, driven by strong performance in diversified end markets and operational efficiencies.
Better than expected
NYSE
CTS
Cts CORPCTS Corporation reported an 8% increase in Q3 net sales to $143 million, driven by diversified markets, but net earnings fell 24.3% to $13.7 million due to higher tax expense and environmental costs.
Capital raise
Worse than expected
NYSE
CTS
Cts CORPCTS Corporation announced significant increases in net earnings and gross margin for the second quarter and first half of 2025, fueled by robust growth in medical, industrial, and aerospace & defense sectors, despite a decline in transportation sales.
Capital raise
Better than expected
NYSE
CTS
Cts CORPCTS Corporation's Q1 2025 results show flat net sales year-over-year but an increase in gross margin driven by improved sales mix and foreign exchange benefits.
NYSE
CTS
Cts CORPCTS Corporation's Q3 2024 results show a slight decrease in net sales but an increase in gross margin, influenced by a recent acquisition and market dynamics.
Worse than expected
Annual Reports (10-K)
NYSE
CTS
Cts CORPCTS Corporation announced a 5.2% increase in net sales and a 17.7% rise in net earnings for 2025, driven by diversified markets and operational improvements.
Better than expected
Capital raise
NYSE
CTS
Cts CORPCTS Corporation's 2024 10-K filing reveals a decrease in net sales primarily due to reduced transportation product volume, offset by growth in diversified end markets and strategic acquisitions.
Delay expected
Worse than expected
NYSE
CTS
Cts CORPCTS Corporation, a global manufacturer of sensors and connectivity components, released its 10-K filing, outlining its financial results, business strategy, and risk factors for the fiscal year ended December 31, 2023.
Worse than expected
Insider Trading (Form 4)
NYSE
CTS
Cts CORPMark R. Pacioni, VP, Chief Legal/Admin. Officer of Cts Corp, reported a transaction in 531 shares of common stock on July 29, 2026.
NYSE
CTS
Cts CORPPratik Trivedi, President & CEO of CTS Corp, acquired 14,253 shares of common stock on July 6, 2026, as part of a restricted stock award.
NYSE
CTS
Cts CORPKieran M. O'Sullivan, President & CEO of CTS Corp, reported the sale of company stock totaling over 129,000 shares across three days in early June 2026, executed under a Rule 10b5-1 trading plan.
NYSE
CTS
Cts CORPJohn M. Hawkins, Senior Vice President at CTS Corp, received restricted stock awards totaling 2,010 shares under the company's 2018 Equity and Incentive Compensation Plan.
NYSE
CTS
Cts CORPCTS Corp Chief Operating Officer Pratik Trivedi reported a transaction involving the surrender of common stock to cover tax withholding obligations.
NYSE
CTS
Cts CORPCTS Corporation's CFO, Ashish Agrawal, acquired 4,310 shares from vested performance units and disposed of 2,024 shares for tax withholding.
Proxy Statements (Def-14A)
NYSE
CTS
Cts CORPCTS Corporation reports 2025 revenue growth of 5% to $541 million and outlines its Evolution 2030 strategic growth plan.
NYSE
CTS
Cts CORPCTS Corporation's annual shareholder meeting is scheduled for May 8, 2025, with proxy materials available online and via mail upon request.
NYSE
CTS
Cts CORPCTS Corporation's 2025 proxy statement outlines proposals for the election of directors, advisory vote on executive compensation, and ratification of the independent auditor.
NYSE
CTS
Cts CORPCTS Corporation's upcoming annual meeting on May 9, 2024, will address director elections, executive compensation, and auditor ratification.
NYSE
CTS
Cts CORPDEF 14A: CTS Corporation Faces Headwinds in 2023, Focuses on Long-Term Strategy and Shareholder Returns
CTS Corporation navigated a challenging 2023 with economic uncertainties and softened demand, while maintaining focus on long-term strategic goals and returning capital to shareholders.
Worse than expected
Schedule 13G - Passive Investments
NYSE
CTS
Cts CORPWasatch Advisors LP has reported an increase in its beneficial ownership of CTS Corp common stock, now holding 12.6% of the class.
NYSE
CTS
Cts CORPWasatch Advisors LP has filed a Schedule 13G, reporting beneficial ownership of 3,121,898 shares of CTS Corp common stock, representing 10.9% of the class.
NYSE
CTS
Cts CORPVanguard Capital Management has filed a Schedule 13G reporting a 5.06% beneficial ownership stake in CTS Corp.
NYSE
CTS
Cts CORPThe Vanguard Group has reported zero beneficial ownership in CTS Corp following an internal realignment where its subsidiaries will now report separately.
NYSE
CTS
Cts CORPWasatch Advisors LP has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in CTS Corp.
NYSE
CTS
Cts CORPSCHEDULE 13G/A: T. Rowe Price Amends CTS CORP Stake to 1.8%
T. Rowe Price Investment Management, Inc. has filed an amendment to its Schedule 13G, reporting a 1.8% beneficial ownership stake in CTS CORP as of September 30, 2025.